Efficacy of SGLTi Vs. GLP1a on cerebral blood flow in people with type 2 diabetes

Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder with numerous health consequences that stem from high levels of sugar in the blood related to insulin resistance. The prevalence of T2DM varies by country, but there is a clear trend towards an increased number of people worldwide living with diabetes. People manage their diabetes through medications and lifestyle, and consequently live longer compared to previous decades; however, there are currently T2DM ‘blind spots’, notably whether diabetes accelerates neurodegeneration, predisposing people to incurable diseases like Alzheimer’s disease. Increasing evidence of recent clinical trials sheds light on the therapeutic benefits of contemporary glucose lowering medications on cardiovascular related outcomes in patients with type 2 diabetes. This proof-of-concept trial will provide evidence if treatment by glucose lowering medications such as Glucagon like Peptide-1 agonists and Sodium Glucose co-transporter-2 inhibitors can mitigate neurodegeneration and c